Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Curis (NASDAQ:CRIS) released its earnings results on Monday. The biotechnology company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.11, Zacks reports. The company had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%.

Curis Stock Down 9.5 %

Shares of NASDAQ:CRIS opened at $2.10 on Tuesday. The firm has a market capitalization of $17.78 million, a PE ratio of -0.27 and a beta of 3.49. The company has a 50-day moving average price of $3.01 and a two-hundred day moving average price of $3.86. Curis has a twelve month low of $2.10 and a twelve month high of $17.49.

Wall Street Analyst Weigh In

Several analysts have commented on CRIS shares. StockNews.com assumed coverage on shares of Curis in a research report on Saturday. They issued a “hold” rating on the stock. HC Wainwright lowered their price target on shares of Curis from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Monday.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.